Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice

Ítems similars

• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
  per: Baek, R, et al.
  Publicat: (2008)
• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
  per: Baek, R, et al.
  Publicat: (2004)
• Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
  per: Kasperzyk, J, et al.
  Publicat: (2002)
• Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice
  per: J.L. Kasperzyk, et al.
  Publicat: (2005-04-01)
• "Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
  per: Kasperzyk, J, et al.
  Publicat: (2005)